markets.businessinsider.com
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025
This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory markers, which may matter to people tracking new therapies beyond injectable biologics.
Adults with Crohn’s disease, patients interested in oral IBD treatments, clinicians treating IBD, and clinical researchers following TYK2-targeted therapies and Phase 2–3 development.
What To Know
Ventyx presented Phase 2 trial results for VTX958, an oral allosteric TYK2 inhibitor, in moderately-to-severely active Crohn’s disease at ECCO 2025.
The press release reports that the trial missed its primary symptomatic endpoint (change in CDAI) but showed dose-dependent, statistically significant endoscopic improvements (SES-CD) and reductions in inflammatory biomarkers (CRP and fecal calprotectin). The company notes safety was favorable and full 52-week data will inform further development.
This is a Phase 2 result announcement and not clinical guidance. The trial did not meet its primary symptomatic endpoint, though endoscopic outcomes and biomarker changes were positive and described as dose-dependent.
The company and external expert quoted emphasize the need for further study; Ventyx highlights potential future roles for VTX958 as an oral therapy alone or in combination with other agents.
If you want the original source: the company press release is posted via GlobeNewswire and was summarized on Business Insider’s Markets site; the poster abstract is listed in the Journal of Crohn’s and Colitis (DOI provided).
These are company-reported Phase 2 results presented as a conference poster; the primary symptomatic endpoint (CDAI) was not met, and the company frames the positive endoscopic and biomarker findings as rationale for further study.
Poster/abstract details and full 52-week data will provide more complete evidence; this announcement alone does not change treatment recommendations.
